1	Medical	Medical	B-NP	JJ	O	2	NMOD	-1
2	therapy	therapy	I-NP	NN	O	0	ROOT	0
3	for	for	B-PP	IN	O	2	NMOD	-1
4	intermittent	intermittent	B-NP	JJ	O	5	NMOD	-1
5	claudication	claudication	I-NP	NN	O	3	PMOD	-1
6	.	.	O	.	O	2	P	-1

1	Medical	Medical	B-NP	JJ	O	2	NMOD	-1
2	therapy	therapy	I-NP	NN	O	7	SUB	0
3	to	to	B-VP	TO	O	4	VMOD	-1
4	improve	improve	I-VP	VB	O	2	NMOD	0
5	symptoms	symptom	B-NP	NNS	O	4	OBJ	-1
6	,	,	O	,	O	2	P	-1
7	stabilise	stabilise	B-VP	VBP	O	0	ROOT	-1
8	the	the	B-NP	DT	O	11	NMOD	-1
9	underlying	underlie	I-NP	VBG	O	11	NMOD	-1
10	vascular	vascular	I-NP	JJ	O	11	NMOD	-1
11	disease	disease	I-NP	NN	O	7	OBJ	-1
12	and	and	O	CC	O	7	VMOD	-1
13	improve	improve	B-VP	VB	O	7	VMOD	0
14	lower	low	B-NP	JJR	O	16	NMOD	-1
15	limb	limb	I-NP	NN	O	16	NMOD	-1
16	outcomes	outcome	I-NP	NNS	O	13	OBJ	-1
17	is	be	B-VP	VBZ	O	7	VMOD	-1
18	an	an	B-NP	DT	O	22	NMOD	-1
19	important	important	I-NP	JJ	O	21	AMOD	0
20	and	and	I-NP	CC	O	21	AMOD	-1
21	effective	effective	I-NP	JJ	O	22	NMOD	0
22	adjunct	adjunct	I-NP	NN	O	30	NMOD	-1
23	to	to	B-PP	TO	O	22	NMOD	-1
24	lifestyle	lifestyle	B-NP	NN	O	25	NMOD	-1
25	modification	modification	I-NP	NN	O	23	PMOD	-1
26	and	and	O	CC	O	30	NMOD	-1
27	surgical	surgical	B-NP	JJ	O	30	NMOD	-1
28	or	or	I-NP	CC	O	30	NMOD	-1
29	endovascular	endovascular	I-NP	JJ	O	30	NMOD	-1
30	interventions	intervention	I-NP	NNS	O	17	PRD	0
31	in	in	B-PP	IN	O	30	NMOD	-1
32	patients	patient	B-NP	NNS	O	31	PMOD	-1
33	with	with	B-PP	IN	O	32	NMOD	-1
34	IC	IC	B-NP	NN	O	33	PMOD	-1
35	.	.	O	.	O	7	P	-1

1	Randomised	Randomise	B-NP	VBN	O	4	NMOD	-1
2	placebo	placebo	I-NP	NN	O	4	NMOD	-1
3	controlled	controlled	I-NP	JJ	O	4	NMOD	0
4	trials	trial	I-NP	NNS	O	5	SUB	-1
5	have	have	B-VP	VBP	O	0	ROOT	-1
6	shown	show	I-VP	VBN	O	5	VC	-1
7	that	that	B-SBAR	IN	O	6	VMOD	-1
8	the	the	B-NP	DT	O	14	NMOD	-1
9	phosphodiesterase	phosphodiesterase	I-NP	NN	O	14	NMOD	-1
10	III	III	I-NP	CD	O	14	NMOD	-1
11	inhibitor	inhibitor	I-NP	NN	O	14	NMOD	0
12	cilostazol	cilostazol	I-NP	NN	O	14	NMOD	-1
13	100mg	100mg	I-NP	CD	O	14	NMOD	-1
14	bid	bid	I-NP	NN	O	15	SUB	-1
15	improves	improve	B-VP	VBZ	O	7	SBAR	0
16	pain-free	pain-free	B-NP	JJ	O	20	NMOD	-1
17	and	and	I-NP	CC	O	20	NMOD	-1
18	maximum	maximum	I-NP	JJ	O	20	NMOD	-1
19	walking	walk	I-NP	VBG	O	20	NMOD	-1
20	distance	distance	I-NP	NN	O	25	NMOD	-1
21	,	,	O	,	O	25	P	-1
22	as	as	B-CONJP	RB	O	25	NMOD	-1
23	well	well	I-CONJP	RB	O	22	DEP	-1
24	as	as	I-CONJP	IN	O	22	DEP	-1
25	quality	quality	B-NP	NN	O	15	OBJ	-1
26	of	of	B-PP	IN	O	25	NMOD	-1
27	life	life	B-NP	NN	O	26	PMOD	-1
28	,	,	O	,	O	15	P	-1
29	in	in	B-PP	IN	O	15	VMOD	-1
30	a	a	B-NP	DT	O	31	NMOD	-1
31	range	range	I-NP	NN	O	29	PMOD	-1
32	of	of	B-PP	IN	O	31	NMOD	-1
33	patients	patient	B-NP	NNS	O	32	PMOD	-1
34	with	with	B-PP	IN	O	33	NMOD	-1
35	intermittent	intermittent	B-NP	JJ	O	36	NMOD	-1
36	claudication	claudication	I-NP	NN	O	34	PMOD	-1
37	in	in	B-PP	IN	O	15	VMOD	-1
38	whom	whom	B-NP	WP	O	37	PMOD	-1
39	there	there	B-NP	EX	O	40	SUB	-1
40	is	be	B-VP	VBZ	O	37	SBAR	-1
41	no	no	B-NP	DT	O	42	NMOD	-1
42	evidence	evidence	I-NP	NN	O	40	PRD	-1
43	of	of	B-PP	IN	O	42	NMOD	-1
44	tissue	tissue	B-NP	NN	O	45	NMOD	-1
45	necrosis	necrosis	I-NP	NN	O	48	NMOD	5	necrosis
46	or	or	O	CC	O	48	NMOD	-1
47	rest	rest	B-NP	NN	O	48	NMOD	-1
48	pain	pain	I-NP	NN	O	43	PMOD	-1
49	.	.	O	.	O	5	P	-1

1	This	This	B-NP	DT	O	2	NMOD	-1
2	review	review	I-NP	NN	O	3	SUB	-1
3	summarises	summarise	B-VP	VBZ	O	0	ROOT	-1
4	the	the	B-NP	DT	O	5	NMOD	-1
5	evidence	evidence	I-NP	NN	O	3	OBJ	-1
6	from	from	B-PP	IN	O	5	NMOD	-1
7	8	8	B-NP	CD	O	9	NMOD	-1
8	pivotal	pivotal	I-NP	JJ	O	9	NMOD	-1
9	trials	trial	I-NP	NNS	O	6	PMOD	-1
10	of	of	B-PP	IN	O	9	NMOD	-1
11	cilostazol	cilostazol	B-NP	NN	O	10	PMOD	-1
12	involving	involve	B-VP	VBG	O	11	NMOD	0
13	over	over	B-PP	IN	O	12	VMOD	-1
14	2000	2000	B-NP	CD	O	15	NMOD	-1
15	patients	patient	I-NP	NNS	O	13	PMOD	-1
16	with	with	B-PP	IN	O	15	NMOD	-1
17	intermittent	intermittent	B-NP	JJ	O	18	NMOD	-1
18	claudication	claudication	I-NP	NN	O	16	PMOD	-1
19	treated	treat	B-VP	VBN	O	18	NMOD	19	treated
20	for	for	B-PP	IN	O	19	VMOD	-1
21	up	up	B-NP	RB	O	24	NMOD	-1
22	to	to	I-NP	TO	O	21	AMOD	-1
23	6	6	I-NP	CD	O	21	AMOD	-1
24	months	month	I-NP	NNS	O	20	PMOD	-1
25	.	.	O	.	O	3	P	-1

1	There	There	B-NP	EX	O	2	SUB	-1
2	is	be	B-VP	VBZ	O	24	VMOD	-1
3	comparatively	comparatively	B-NP	RB	O	4	AMOD	-1
4	less	less	I-NP	JJR	O	5	NMOD	-1
5	evidence	evidence	I-NP	NN	O	2	PRD	-1
6	to	to	B-VP	TO	O	7	VMOD	-1
7	support	support	I-VP	VB	O	5	NMOD	0
8	the	the	B-NP	DT	O	9	NMOD	-1
9	use	use	I-NP	NN	O	7	OBJ	0
10	of	of	B-PP	IN	O	9	NMOD	-1
11	other	other	B-NP	JJ	O	13	NMOD	-1
12	treatment	treatment	I-NP	NN	O	13	NMOD	0
13	modalities	modality	I-NP	NNS	O	10	PMOD	-1
14	for	for	B-PP	IN	O	9	NMOD	-1
15	relief	relief	B-NP	NN	O	14	PMOD	-1
16	of	of	B-PP	IN	O	15	NMOD	-1
17	symptoms	symptom	B-NP	NNS	O	16	PMOD	-1
18	in	in	B-PP	IN	O	15	NMOD	-1
19	intermittent	intermittent	B-NP	JJ	O	20	NMOD	-1
20	claudication	claudication	I-NP	NN	O	18	PMOD	-1
21	,	,	O	,	O	24	P	-1
22	but	but	O	CC	O	24	VMOD	-1
23	there	there	B-NP	EX	O	24	SUB	-1
24	is	be	B-VP	VBZ	O	0	ROOT	-1
25	considerable	considerable	B-NP	JJ	O	26	NMOD	-1
26	interest	interest	I-NP	NN	O	24	PRD	-1
27	in	in	B-PP	IN	O	26	NMOD	-1
28	therapeutic	therapeutic	B-NP	JJ	O	29	NMOD	-1
29	angiogenesis	angiogenesis	I-NP	NN	O	27	PMOD	3	angiogenesis
30	to	to	B-VP	TO	O	31	VMOD	-1
31	promote	promote	I-VP	VB	O	24	VMOD	17	promote
32	new	new	B-NP	JJ	O	34	NMOD	-1
33	vessel	vessel	I-NP	NN	O	34	NMOD	-1
34	formation	formation	I-NP	NN	O	31	OBJ	2	formation
35	and	and	O	CC	O	24	VMOD	-1
36	enhance	enhance	B-VP	VBP	O	24	VMOD	17	enhance
37	collateralisation	collateralisation	B-NP	NN	O	36	OBJ	3	collateralisation
38	of	of	B-PP	IN	O	37	NMOD	-1
39	the	the	B-NP	DT	O	41	NMOD	-1
40	lower	low	I-NP	JJR	O	41	NMOD	-1
41	limb	limb	I-NP	NN	O	38	PMOD	-1
42	using	use	B-VP	VBG	O	36	VMOD	-1
43	recombinant	recombinant	B-NP	JJ	B-protein	46	NMOD	-1
44	growth	growth	I-NP	NN	I-protein	46	NMOD	0
45	factor	factor	I-NP	NN	I-protein	46	NMOD	-1
46	proteins	protein	I-NP	NNS	I-protein	50	NMOD	-1
47	or	or	O	CC	O	50	NMOD	-1
48	gene	gene	B-NP	NN	O	50	NMOD	-1
49	transfer	transfer	I-NP	NN	O	50	NMOD	-1
50	strategies	strategy	I-NP	NNS	O	42	OBJ	-1
51	.	.	O	.	O	24	P	-1

1	The	The	B-NP	DT	O	2	NMOD	-1
2	rationale	rationale	I-NP	NN	O	6	SUB	-1
3	for	for	B-PP	IN	O	2	NMOD	-1
4	therapeutic	therapeutic	B-NP	JJ	O	5	NMOD	-1
5	angiogenesis	angiogenesis	I-NP	NN	O	3	PMOD	3	angiogenesis
6	is	be	B-VP	VBZ	O	0	ROOT	-1
7	discussed	discuss	I-VP	VBN	O	6	VC	-1
8	,	,	O	,	O	7	P	-1
9	together	together	B-ADVP	RB	O	7	VMOD	-1
10	with	with	B-PP	IN	O	7	VMOD	-1
11	the	the	B-NP	DT	O	14	NMOD	-1
12	most	most	I-NP	RBS	O	13	AMOD	-1
13	recent	recent	I-NP	JJ	O	14	NMOD	-1
14	results	result	I-NP	NNS	O	10	PMOD	0
15	from	from	B-PP	IN	O	14	NMOD	-1
16	randomised	randomise	B-NP	VBN	O	17	NMOD	-1
17	trials	trial	I-NP	NNS	O	15	PMOD	-1
18	in	in	B-PP	IN	O	17	NMOD	-1
19	patients	patient	B-NP	NNS	O	18	PMOD	-1
20	with	with	B-PP	IN	O	19	NMOD	-1
21	peripheral	peripheral	B-NP	JJ	O	23	NMOD	-1
22	arterial	arterial	I-NP	JJ	O	23	NMOD	-1
23	disease	disease	I-NP	NN	O	20	PMOD	-1
24	.	.	O	.	O	6	P	-1

